Exomphalos (Omphalocele)

1. Clinical Overview

Summary

Exomphalos (also known as omphalocele) is a congenital anterior abdominal wall defect in which abdominal contents (bowel, liver, spleen, and occasionally other organs) herniate through the umbilical ring and are covered by a translucent tri-layered membrane composed of peritoneum (inner layer), Wharton's jelly (middle layer), and amnion (outer layer). [1] The umbilical cord inserts directly onto the apex of the sac, distinguishing it anatomically from gastroschisis. Unlike gastroschisis, which is typically an isolated defect, exomphalos is strongly associated with chromosomal abnormalities (trisomies 13, 18, 21), genetic syndromes (especially Beckwith-Wiedemann syndrome), and structural anomalies, with 50-70% of cases having significant associated anomalies. [2,3]

The incidence is approximately 3.38 per 10,000 live births, though antenatal detection rates have improved significantly with widespread anomaly scanning. [4] Management strategy depends primarily on defect size and associated anomalies rather than the abdominal wall defect alone. Small defects (exomphalos minor, less than 5cm diameter, containing bowel only) are amenable to primary surgical closure within the first 24-48 hours of life. Large and giant defects (greater than 5cm, containing liver) present a surgical challenge due to viscero-abdominal disproportion and may require staged closure using a silo reduction technique or conservative "paint and wait" management with topical agents promoting escharification. [5,6]

Prognosis is determined predominantly by associated anomalies rather than the abdominal wall defect itself. Isolated exomphalos minor has excellent prognosis with greater than 95% survival, whereas giant exomphalos with major chromosomal or cardiac anomalies carries significantly higher mortality. [7,8]

Key Facts

• Definition: Midline abdominal wall defect at umbilicus with herniation of viscera into a membrane-covered sac
• Incidence: 3.38 per 10,000 pregnancies (1 in 4,000-7,000 live births)
• Key differentiator: Covered by tri-layered membrane with umbilical cord insertion on sac (vs gastroschisis which is uncovered, lateral to umbilicus, with normal cord insertion)
• Associated anomalies: 50-70% (chromosomal abnormalities 30-40%, cardiac defects 30-50%, Beckwith-Wiedemann syndrome 5-10%)
• Classification: Minor (less than 5cm, bowel only) vs Major/Giant (greater than 5cm, contains liver)
• Antenatal detection: Usually detected on first-trimester (11-13 weeks) or anomaly scan (18-20 weeks)
• Survival: Overall 75-85%, but 95% for isolated defects vs 40-60% for those with major chromosomal abnormalities

Clinical Pearls

"Exomphalos = Anomalies": Up to 50-70% of exomphalos cases have associated chromosomal or structural anomalies. Always perform karyotyping and detailed cardiac echocardiography. The defect is rarely isolated, unlike gastroschisis where 85-90% are isolated anomalies. [2,3]

"In the Cord vs Beside the Cord": Exomphalos is IN the umbilical cord (central, covered by membrane, cord inserts on sac). Gastroschisis is BESIDE the cord (lateral, typically right paraumbilical, uncovered bowel, normal cord insertion). This anatomical distinction is critical for prognosis, associated anomalies, and management planning. [9]

"Paint and Wait": For giant exomphalos where primary closure is impossible due to viscero-abdominal disproportion, topical agents (silver sulfadiazine, povidone-iodine, or Manuka honey) promote eschar formation over the intact sac, allowing gradual epithelialisation over weeks to months before delayed surgical repair. This conservative approach avoids the respiratory and haemodynamic compromise of forced reduction. [6,10]

"Respiratory Insufficiency Predicts Mortality": Respiratory insufficiency at birth is an independent predictor of mortality in exomphalos patients. Pulmonary hypoplasia and pulmonary hypertension are particularly concerning in giant exomphalocele, resulting from restricted thoracic space during fetal development. [11,12]

Why This Matters Clinically

Antenatal diagnosis (now achievable in over 90% of cases at 11-13 week scan for major defects) allows critical prenatal counselling, chromosomal testing, detailed fetal echocardiography, and planned delivery at a tertiary centre with neonatal surgical facilities. [13] The key clinical challenge is comprehensive assessment and management of associated anomalies—particularly cardiac defects (30-50%), chromosomal abnormalities (30-40%), and pulmonary hypoplasia—which drive prognosis more than the abdominal wall defect itself. [7,8,14] The multidisciplinary approach involving fetal medicine, neonatology, paediatric surgery, genetics, and cardiology is essential for optimising outcomes.

---

2. Epidemiology

Incidence & Prevalence

• Incidence: 3.38 per 10,000 pregnancies; 1 in 4,000-7,000 live births [4]
• Trend: Stable overall incidence; apparent decreases in some registries reflect increased antenatal detection and termination of pregnancy for severe associated anomalies
• Association with maternal age: Increased incidence with advanced maternal age (related to chromosomal associations, particularly trisomies 13 and 18) [2]
• Antenatal detection rate: Greater than 90% for major defects; 75-85% overall when anomaly scanning is routine [13]
• Live birth prevalence: Lower than pregnancy prevalence due to termination of pregnancy for severe anomalies and intrauterine fetal demise

Demographics

Risk Factors

Non-Modifiable:

• Advanced maternal age (greater than 35 years)
• Chromosomal abnormalities in fetus (trisomies 13, 18, 21)
• Genetic syndromes (Beckwith-Wiedemann syndrome, Donnai-Barrow syndrome, Kagami-Ogata syndrome)
• Family history (rare familial cases, particularly with syndromic associations)

Potentially Modifiable:

Epidemiological Comparison: Exomphalos vs Gastroschisis

---

3. Pathophysiology

Embryological Basis

Normal Abdominal Wall Development:

• Week 4-5: Lateral body folds begin to migrate ventrally
• Week 6: Physiological midgut herniation occurs into the umbilical cord (normal developmental process)
• Week 10-12: Midgut returns to the abdominal cavity with 270-degree counter-clockwise rotation
• Week 10-12: Lateral body folds complete fusion at the midline, forming the intact abdominal wall
• Week 12: Umbilical ring contracts around the umbilical vessels

Abnormal Development in Exomphalos:

Exomphalos results from failure of closure of the ventral body wall at the umbilical ring. The precise embryological mechanism remains debated, with several theories: [15]

1. Failure of lateral body fold migration: The most widely accepted theory suggests incomplete or arrested migration of the lateral body folds toward the midline during weeks 6-10, resulting in persistence of the physiological hernia
2. Failure of midgut return: Arrested or incomplete return of the physiological midgut herniation into the abdominal cavity
3. Primary abdominal wall defect: A primary defect in the development of the abdominal musculature and/or connective tissue
4. Yolk sac regression failure: Abnormal persistence or regression of yolk sac structures

The herniated contents remain covered by a tri-layered membrane:

• Inner layer: Peritoneum
• Middle layer: Wharton's jelly (gelatinous connective tissue of the umbilical cord)
• Outer layer: Amnion

The umbilical cord vessels course through the membrane and insert at the apex of the sac, a pathognomonic feature distinguishing exomphalos from gastroschisis. [1]

Classification Systems

By Size (Most Clinically Relevant):

Alternative Classification (by Abdominal Domain):

Giant exomphalos can be defined functionally as viscero-abdominal disproportion preventing primary fascial closure without causing abdominal compartment syndrome. This functional definition is increasingly preferred over arbitrary size measurements. [6]

By Sac Integrity:

• Intact sac: Standard management applicable
• Ruptured sac: Surgical emergency; exposed viscera require urgent protection and expedited closure

Exomphalos vs Gastroschisis: Pathophysiological Differences

The distinction is usually straightforward on prenatal ultrasound and at birth, but small exomphalos can occasionally be confused with gastroschisis or umbilical cord hernia. [9,16]

Rare Variants

Exomphalos with Intestinal Fistulation (EIF):

A rare variant where the intestine opens to the surface of an intact exomphalos sac, often creating diagnostic uncertainty. [23]

Incidence: Rare; fewer than 60 cases reported globally [23]

Anatomical Features:

• Intestinal lumen communicates directly with the external surface of the intact sac
• Fistula typically located at the apex or lateral aspect of the sac
• Associated with persistent vitellointestinal duct remnants in some cases
• May present with meconium or intestinal contents visible on sac surface

Diagnostic Challenge:

• Can be mistaken for sac rupture, gastroschisis, or omphalomesenteric duct anomaly
• Antenatal diagnosis difficult; often identified postnatally when intestinal content observed leaking from intact sac

Management:

• Requires surgical repair with fistula excision and bowel closure
• Outcomes generally good if recognized and treated promptly [23]

Clinical Pearl: If intestinal contents are visible on the surface of what appears to be an intact sac, consider EIF rather than assuming sac rupture. Careful inspection at surgery is essential.

---

4. Associated Anomalies and Syndromes

Frequency of Associated Anomalies

Associated structural and chromosomal anomalies are present in 50-70% of exomphalos cases, profoundly impacting prognosis. [2,3,14]

Major Categories:

Chromosomal Abnormalities

Trisomy 18 is the most commonly associated chromosomal abnormality and carries a very poor prognosis with most infants dying in the neonatal period. [2]

Beckwith-Wiedemann Syndrome (BWS)

BWS is an overgrowth disorder affecting 5-10% of infants with exomphalos. [17,18]

Cardinal Features:

• Macroglossia (large tongue)
• Macrosomia (birth weight greater than 90th centile)
• Omphalocele (present in approximately 75% of BWS cases)
• Hemihyperplasia (asymmetrical overgrowth)
• Visceromegaly (enlarged organs, particularly liver, kidneys, pancreas)
• Ear creases/pits (posterior helical pits)
• Neonatal hypoglycaemia (due to hyperinsulinism; present in 50%)

Genetic Mechanisms:

• Alterations in chromosome 11p15.5 imprinted region
• Loss of methylation at IC2 (most common, 50%)
• Gain of methylation at IC1 (5-10%)
• Paternal uniparental disomy of 11p15 (20%)
• CDKN1C pathogenic variants (5-10%)
• Chromosome 11p15 duplications, inversions, or translocations (rare)

Genotype-Phenotype Correlations: [24,25]

Different molecular subtypes of BWS have distinct clinical features and tumour risks:

Key Clinical Implication: BWS patients with CDKN1C variants have a distinctly different tumour risk profile. Traditional screening for Wilms tumour and hepatoblastoma may not be necessary; instead, screening for neuroblastoma should be considered. [25]

Clinical Implications:

• Tumour risk: Varies by genotype (see table above)
• Surveillance protocols should be genotype-specific:
  • "IC2 LOM: Standard abdominal USS every 3 months until age 7-8 years; serum AFP every 3 months until age 4 years"
  • "IC1 GOM/UPD: Intensive surveillance (higher tumour risk)"
  • "CDKN1C variants: Consider neuroblastoma screening (urinary catecholamines); Wilms/hepatoblastoma screening may be unnecessary"
• Hypoglycaemia management: Frequent glucose monitoring; may require diazoxide or octreotide
• Macroglossia: May require tongue reduction surgery if causing airway obstruction or feeding difficulties

Recognition of BWS in an infant with exomphalos is critical for initiating appropriate genotype-specific tumour surveillance protocols. [17,18,24,25]

Cardiac Anomalies

Congenital heart disease is present in 30-50% of infants with exomphalos, making echocardiography mandatory in all cases. [14]

Common Defects:

• Ventricular septal defect (VSD): Most common
• Atrial septal defect (ASD)
• Tetralogy of Fallot (TOF)
• Hypoplastic left heart syndrome (HLHS)
• Atrioventricular septal defect (AVSD): Particularly with trisomy 21
• Coarctation of the aorta
• Patent ductus arteriosus (PDA)

Cardiac defects significantly impact surgical decision-making and anaesthetic risk, and may preclude or delay abdominal wall repair in unstable infants.

Pulmonary Hypoplasia and Hypertension

Pulmonary complications are increasingly recognised, particularly in giant exomphalos. [11,12]

Mechanisms:

• Reduced thoracic space: Viscero-abdominal disproportion causes upward displacement of diaphragm, limiting lung expansion during fetal development
• Pulmonary hypoplasia: Reduced alveolar number and lung volume
• Pulmonary hypertension: Abnormal pulmonary vascular development; increased pulmonary vascular resistance
• Persistent pulmonary hypertension of the newborn (PPHN): Can be life-threatening

Clinical Implications:

• Respiratory insufficiency at birth is an independent predictor of mortality [11]
• May require prolonged ventilatory support, inhaled nitric oxide, or ECMO
• Surgical closure can worsen respiratory function by further reducing thoracic volume
• Conservative "paint and wait" approach may be preferred in severe pulmonary compromise

Other Syndromic Associations

---

5. Clinical Presentation

Antenatal Presentation

First-Trimester Ultrasound (11-13 Weeks):

Exomphalos can be detected as early as 11-13 weeks' gestation with high-quality ultrasound. [13]

Ultrasound Findings:

• Mass arising from anterior abdominal wall at the umbilicus
• Covered by echogenic membrane (visible as thin bright line)
• Umbilical cord inserts into the apex of the sac
• Contents visible within sac: hyperechoic (bowel loops) or hypoechoic (liver)
• Defect size measurable (useful for predicting primary closure feasibility)

Pitfall - Physiological Herniation:

• Normal midgut herniation occurs until 12 weeks' gestation
• Diagnosis of exomphalos should be made with caution before 12 weeks
• Follow-up scan at 13-14 weeks recommended if detected at 11-12 weeks to confirm persistence

Second-Trimester Anomaly Scan (18-22 Weeks):

This is the definitive diagnostic window for exomphalos. Detection rate approaches 90-95% for major defects. [13]

Detailed Assessment:

• Defect size: Measure maximum diameter; calculate EDmax/AC ratio (ratio of maximum exomphalos diameter to abdominal circumference)
  • EDmax/AC ratio less than 0.24 predicts feasibility of primary closure with 85% accuracy [19]
• Sac integrity: Assess for rupture (rare antenatally)
• Contents: Bowel only (minor) vs liver-containing (major/giant)
• Liver herniation: Percentage of liver outside abdomen; greater than 75% liver herniation associated with poorer outcomes
• Associated anomalies: Detailed fetal survey including cardiac, renal, CNS, skeletal
• Chromosomal markers: Increased nuchal translucency, absent nasal bone, etc.

Fetal Echocardiography:

Mandatory in all cases; should be performed at 18-22 weeks by specialist fetal cardiologist. [14]

Genetic Testing:

Invasive testing options:

• Amniocentesis (after 15 weeks): Karyotype, chromosomal microarray
• Chorionic villus sampling (CVS) (11-14 weeks): If early diagnosis and high suspicion of aneuploidy

Non-invasive prenatal testing (NIPT):

• Cell-free fetal DNA screening for trisomies 13, 18, 21
• High sensitivity/specificity but requires confirmatory invasive testing if positive

Indications for invasive testing:

• All cases of exomphalos (30-40% have chromosomal abnormalities)
• Particularly if associated structural anomalies detected
• If BWS suspected: methylation studies of chromosome 11p15

Counselling:

Comprehensive multidisciplinary counselling should be offered: [7]

• Fetal medicine specialist
• Paediatric surgeon
• Neonatologist
• Clinical geneticist
• Options discussion (continue pregnancy vs termination, particularly for lethal chromosomal abnormalities)

Postnatal Presentation

Appearance at Birth:

Intact Sac:

• Central abdominal mass at umbilicus
• Covered by translucent, glistening membrane (may be thin or thick)
• Umbilical cord arises from the apex of the sac (pathognomonic feature)
• Bowel loops visible through membrane (peristalsis may be observed)
• Liver appears as solid, darker mass within sac if present
• Sac may be tense or lax depending on contents

Ruptured Sac (5-10% of cases):

• Exposed viscera (bowel, liver)
• Membrane torn or absent
• Emergency situation requiring immediate coverage and expedited surgery
• Higher mortality (20-30%) due to infection, hypothermia, fluid loss [20]

Size Assessment:

• Small (exomphalos minor): Less than 5cm; bowel only; relatively soft, reducible
• Medium: 5-10cm; bowel and partial liver
• Giant: Greater than 10cm; majority of liver, bowel, spleen, stomach; tense, non-reducible

Associated Features to Assess:

Beckwith-Wiedemann Syndrome:

• Macroglossia: Large protruding tongue
• Macrosomia: Birth weight greater than 90th centile (often greater than 4kg at term)
• Ear creases/pits: Posterior helical ear pits (small indentations)
• Hemihyperplasia: Asymmetrical limb or body overgrowth
• Hypoglycaemia: Common in first 48 hours; may be severe

Chromosomal Abnormalities:

• Trisomy 18: Clenched fists with overlapping fingers, rocker-bottom feet, micrognathia, low-set ears
• Trisomy 13: Microcephaly, cleft lip/palate, polydactyly, scalp defects
• Trisomy 21: Flat facial profile, upslanting palpebral fissures, single palmar crease, hypotonia

Cardiac:

• Murmur (suggests structural heart disease)
• Cyanosis (cyanotic heart disease or PPHN)
• Signs of heart failure (tachypnoea, hepatomegaly, poor perfusion)

Respiratory:

• Tachypnoea, grunting, retractions (respiratory distress)
• Desaturation (pulmonary hypoplasia, PPHN, or cardiac defect)
• Cyanosis unresponsive to oxygen (severe PPHN or cyanotic heart disease)

Red Flags

[!CAUTION] Red Flags — Urgent/Emergency action required if:

• Ruptured sac (exposed bowel/liver — cover immediately with warm saline-soaked dressings and cling film; emergency surgery)
• Signs of bowel ischaemia (discolouration, dusky or necrotic appearance of bowel visible in sac)
• Severe respiratory distress (grunting, severe retractions, desaturation less than 85% on oxygen; suggests pulmonary hypoplasia or PPHN)
• Hypoglycaemia (blood glucose less than 2.6 mmol/L; particularly with BWS — urgent IV dextrose; frequent monitoring)
• Signs of cardiac failure (tachypnoea, poor perfusion, hepatomegaly, gallop rhythm; suggests critical CHD)
• Abdominal compartment syndrome (after closure: tense abdomen, rising ventilatory pressures, oliguria, hypotension; requires immediate decompression)
• Sepsis (temperature instability, lethargy, poor feeding, cardiovascular instability; particularly if ruptured sac)

---

6. Clinical Examination

Structured Approach

General Assessment:

Airway and Breathing:

• Airway patency (macroglossia may obstruct airway in BWS)
• Respiratory rate and effort (retractions, grunting)
• Oxygen saturations (baseline and response to oxygen)
• Chest auscultation (air entry, crepitations)

Cardiovascular:

• Heart rate, capillary refill time, blood pressure
• Heart sounds (murmurs, gallops)
• Femoral pulses (assess for coarctation)
• Perfusion (peripheral temperature, colour, urine output)

General Appearance:

• Gestational age assessment (Ballard score if preterm)
• Dysmorphic features (chromosomal abnormalities)
• Birth weight (macrosomia suggests BWS; IUGR uncommon in exomphalos unlike gastroschisis)
• Overall tone and activity

Abdominal Examination:

Inspection:

• Sac integrity: Intact vs ruptured?
• Defect size: Estimate diameter (small less than 5cm, medium 5-10cm, giant greater than 10cm)
• Sac contents: Bowel only (loops visible, peristalsis) vs liver-containing (solid, dark mass)
• Sac tension: Tense (giant, non-reducible) vs lax (minor, may be reducible)
• Umbilical cord: Confirm insertion at apex of sac (pathognomonic)
• Surrounding skin: Intact, any erythema or signs of infection

DO NOT:

• Attempt to reduce contents (risks bowel injury, sac rupture, haemodynamic compromise)
• Remove membrane (if intact)
• Apply excessive pressure

Palpation (Gentle):

• Assess sac for tension
• Identify liver edge if liver herniated
• Assess for other masses (spleen, stomach)

Systematic Examination for Associated Anomalies:

Special Examinations and Monitoring

---

7. Investigations

Immediate Postnatal (First Hours)

Bedside Tests:

• Blood glucose: Urgent; repeat every 1-2 hours initially if BWS suspected or first reading low
• Observations: Continuous oxygen saturation monitoring, heart rate, respiratory rate, temperature
• Blood gas: Venous or arterial if respiratory distress present (assess pH, pCO2, lactate)

Laboratory Tests:

Imaging

Echocardiography (Urgent):

Mandatory in all cases; perform within first 24 hours if stable, urgently if murmur or cyanosis. [14]

Indications:

• 30-50% have structural heart disease
• Identifies defects requiring medical management (PDA, PPHN) or surgical intervention
• Informs anaesthetic risk and surgical timing

Findings to assess:

• Structural defects (VSD, ASD, TOF, HLHS, AVSD, coarctation)
• Functional assessment (ventricular function, pulmonary pressures)
• Patent ductus arteriosus (may require prostaglandin infusion if duct-dependent lesion)

Chest X-ray:

Indications:

• Respiratory distress
• Assessment for pulmonary hypoplasia
• Pre-operative baseline

Findings:

• Small lung volumes (pulmonary hypoplasia)
• Cardiomegaly (cardiac defect)
• Infiltrates (infection, aspiration)
• Pneumothorax (rare; post-ventilation)

Abdominal Ultrasound (Renal and Pelvic):

Indications:

• Screen for renal anomalies (present in 15-25%)
• All cases should have renal ultrasound within first week

Findings:

• Renal agenesis (unilateral or bilateral)
• Renal dysplasia
• Hydronephrosis
• Multicystic dysplastic kidney
• Horseshoe kidney

Cranial Ultrasound:

Indications:

• Dysmorphic features suggesting syndrome
• Trisomy 18 or 13 (CNS anomalies common)
• Suspected Donnai-Barrow or other syndrome

Findings:

• Agenesis of corpus callosum
• Ventriculomegaly
• Intracranial haemorrhage (rare)

Genetic Testing

Karyotype (Chromosomal Analysis):

Indications:

• All cases of exomphalos (30-40% have chromosomal abnormalities) [2]
• Urgent if dysmorphic features present

Timing:

• Send blood sample (1-2mL in lithium heparin) on day 1
• Results typically available in 5-10 days (rapid FISH available for common trisomies in 24-48 hours)

Findings:

• Trisomy 18 (Edwards syndrome): 10-15%
• Trisomy 13 (Patau syndrome): 5-10%
• Trisomy 21 (Down syndrome): 5-8%
• Turner syndrome (45,X): 1-2%
• Other aneuploidies: rare

Chromosomal Microarray:

Indications:

• Normal karyotype but syndromic features present
• Detects submicroscopic deletions/duplications (copy number variants)

Beckwith-Wiedemann Syndrome Testing:

Indications:

• Macroglossia, macrosomia, ear creases/pits, hemihyperplasia, or neonatal hypoglycaemia

Tests:

• Methylation analysis of 11p15.5: Detects IC1 or IC2 methylation defects (55-60% of BWS)
• CDKN1C sequencing: Detects pathogenic variants (5-10% of BWS, higher if familial)
• Chromosomal microarray: Detects duplications/deletions of 11p15 (1-2%)
• Uniparental disomy (UPD) testing: Detects paternal UPD of chromosome 11p15 (20%)

Other Genetic Testing:

If specific syndrome suspected based on phenotype (e.g., LRP2 for Donnai-Barrow syndrome, chromosome 14 methylation for Kagami-Ogata syndrome), targeted genetic testing can be arranged through clinical genetics.

---

8. Management

Management Algorithm

EXOMPHALOS DETECTED AT BIRTH
           |
           ├─ Intact sac ──────────┐
           └─ Ruptured sac ─────┐  |
                                |  |
                         EMERGENCY MEASURES
                         - Cover with warm saline-soaked dressings + cling film
                         - Immediate surgical review
                         - Broad-spectrum antibiotics
                         - Expedited closure
                                |
                                ↓
                      STABILISATION (All Cases)
                      - Keep NBM
                      - IV access + fluids (10% dextrose initially)
                      - NGT on free drainage
                      - Temperature control (incubator/radiant heater)
                      - Protect sac (saline-soaked gauze + cling film)
                      - Position: lateral (prevents vascular compression)
                      - Vitamin K
                      - Bloods: FBC, U&E, glucose, coag, group & save
                                |
                                ↓
                   INVESTIGATE FOR ASSOCIATED ANOMALIES
                   - Echocardiogram (urgent)
                   - Renal ultrasound
                   - Blood glucose monitoring
                   - Karyotype
                   - BWS testing if features present
                                |
                                ↓
                        SIZE ASSESSMENT
                                |
        ┌───────────────────────┼───────────────────────┐
        |                       |                       |
   MINOR (less than 5cm)            MAJOR (5-10cm)       GIANT (less than 10cm)
  Bowel only              Bowel + partial liver  Liver majority
        |                       |                       |
        ↓                       ↓                       ↓
 PRIMARY CLOSURE        ASSESS FEASIBILITY      VISCERO-ABDOMINAL
 (24-48 hours)          - Trial of reduction     DISPROPORTION
                        - Intra-abdominal              |
                          pressure monitoring          |
                                |               ┌──────┴──────┐
                    ┌───────────┴───────────┐  |             |
                    |                       |  ↓             ↓
              PRIMARY CLOSURE         STAGED CLOSURE   PAINT & WAIT
              (if feasible)           - Silo bag       - Silver sulfadiazine
                                      - Gradual           OR povidone-iodine
                                        reduction          OR Manuka honey
                                      - Closure after    - Eschar formation
                                        7-14 days        - Delayed closure
                                                           (months-years)

Immediate Postnatal Care (First Hour)

"Protect the Sac":

Intact Sac:

1. Do NOT attempt reduction of contents
2. Wrap sac in warm saline-soaked gauze (0.9% NaCl, warmed to 37°C)
3. Cover with cling film (sterile plastic wrap) to prevent heat and fluid loss
4. Position baby on side or in slight head-up position (prevents kinking of mesenteric vessels in sac)
5. Avoid pressure on sac (no clothing over defect)

Ruptured Sac:

1. Immediate coverage with warm saline-soaked dressings
2. Cling film over dressings
3. Broad-spectrum antibiotics (e.g., IV benzylpenicillin plus gentamicin)
4. Urgent surgical review (emergency closure required)

Supportive Care:

Investigation for Associated Anomalies:

Within First 24 Hours:

• Echocardiogram (urgent; identifies CHD in 30-50%)
• Blood glucose monitoring (hourly initially if BWS suspected)
• Karyotype (send blood sample)
• Renal ultrasound (can be done in first week if stable)

Surgical Management

Management strategy depends on defect size, sac integrity, associated anomalies, and overall infant stability. [5,6,21]

Exomphalos Minor (Primary Closure)

Definition: Defect less than 5cm diameter; bowel only (no liver); minimal viscero-abdominal disproportion.

Approach:

1. Timing: Within 24-48 hours of birth (once stabilised and anomalies assessed)
2. Anaesthesia: General anaesthesia; intubation and ventilation
3. Technique:
   • Excise sac membrane (may preserve umbilical cord stump for later umbilicoplasty)
   • Reduce bowel contents into abdominal cavity
   • Assess for associated anomalies (malrotation, Meckel's diverticulum)
   • Primary fascial closure (suture rectus sheath)
   • Skin closure (may require undermining)
   • Monitor intra-abdominal pressure (bladder pressure monitoring): aim for less than 20 mmHg to avoid abdominal compartment syndrome

Intra-abdominal Pressure Monitoring:

• Via bladder catheter (transduce pressure)
• Normal: Less than 10 mmHg
• Elevated: 10-20 mmHg (acceptable if ventilation/perfusion adequate)
• Abdominal compartment syndrome: Greater than 20 mmHg (associated with oliguria, hypotension, high ventilatory pressures)
• Action if IAP greater than 20 mmHg: Abort primary closure; proceed to staged closure

Post-operative Care:

• Ventilatory support (may need 24-72 hours)
• NGT decompression (until bowel function returns)
• IV fluids and TPN (until feeding established)
• Monitor for complications (wound dehiscence, infection, ileus)

Outcomes:

• Excellent; greater than 95% survival if isolated defect [7]
• Feeding established within 7-14 days typically
• Hospital stay: 2-4 weeks

Exomphalos Major/Giant (Staged Closure with Silo)

Definition: Defect 5-10cm (major) or greater than 10cm (giant); contains liver; significant viscero-abdominal disproportion.

Indications for Staged Closure:

• Defect too large for primary closure without excessive tension
• Intra-abdominal pressure would exceed 20 mmHg with primary closure
• Respiratory compromise anticipated with primary closure
• Infant stable enough for general anaesthesia but primary closure not feasible

Technique:

1. Silo placement (within 24-72 hours):
   • Pre-formed spring-loaded silo OR custom silo sutured to fascial edge
   • Silo is a transparent silicone bag that contains the herniated organs externally
   • Allows gradual reduction over 7-14 days
2. Gradual reduction:
   • Daily or twice-daily manual compression of silo to reduce contents into abdomen
   • Monitor for signs of bowel ischaemia (discolouration visible through silo)
   • Monitor intra-abdominal pressure, ventilation, urine output
3. Definitive closure (after 7-14 days):
   • Once contents fully reduced
   • Fascial closure (may require mesh if fascial gap persists)
   • Skin closure

Silo Management:

• Keep silo vertical (gravity assists reduction)
• Sterile technique for manipulation
• Monitor for infection (silo is a foreign body)

Outcomes:

• Survival 70-90% if isolated giant exomphalos [7,8]
• Higher morbidity than primary closure (longer ventilation, longer hospital stay)
• Feeding established within 3-6 weeks typically
• Hospital stay: 4-8 weeks

Giant Exomphalos ("Paint and Wait" Conservative Management)

Definition: Giant exomphalos (greater than 10cm; liver-predominant) with severe viscero-abdominal disproportion OR infant too unstable for surgery (severe pulmonary hypoplasia, critical cardiac defect, extreme prematurity).

Indications: [6,10,26]

• Giant exomphalos where primary/staged closure would cause life-threatening respiratory or haemodynamic compromise
• Severe associated anomalies precluding surgery
• Parental preference for conservative approach
• Resource-limited settings (no neonatal surgery available)

2023 Systematic Review of Topical Agents: [26]

A comprehensive systematic review analysed 50 years of evidence on topical substances for conservative exomphalos management, examining 18 different agents across 127 studies.

Topical Agents and Outcomes:

2023 Systematic Review Conclusions: [26]

• Silver sulfadiazine and povidone-iodine remain the most commonly used and best-studied agents
• Manuka honey shows promise with faster epithelialisation and lower infection rates, but evidence base is limited
• Mercurochrome should be abandoned due to mercury toxicity risk
• No agent demonstrates clear superiority in randomised trials (such trials do not exist)
• All agents achieve successful epithelialisation in 85-95% of cases
• Key success factors: Consistent application technique, infection prevention, nutritional support

Technique:

1. Topical agent application to intact sac:
   • Silver sulfadiazine 1% cream: Most commonly used; antimicrobial
   • Povidone-iodine solution: Alternative; antimicrobial (monitor thyroid function in prolonged use)
   • Manuka honey (medical-grade): Emerging agent; antimicrobial, promotes granulation
   • Applied 1-2 times daily with sterile technique
2. Eschar formation: Over 2-4 weeks, sac desiccates and forms thick eschar (dry, leathery covering)
3. Epithelialisation: Over 2-6 months, epithelial tissue grows over eschar from wound edges
4. Delayed surgical closure: Performed at 6 months to 5 years of age once eschar/epithelium mature and infant larger

Advantages:

• Avoids respiratory/haemodynamic compromise of early closure
• No general anaesthesia in unstable neonate
• Allows immediate breastfeeding (contrasts with surgical approach requiring prolonged NBM and TPN)
• Shorter initial hospital stay (4-6 weeks vs 8-12 weeks for staged closure) [10,26]

Disadvantages:

• Prolonged time to definitive closure (months to years)
• Large ventral hernia persists until delayed closure
• Risk of sac rupture during conservative management (requires emergency surgery)
• Aesthetic concerns (large abdominal protrusion)
• Requires caregiver commitment to daily wound care

Outcomes:

• Comparable survival to staged closure for giant exomphalos (85-90% if isolated) [10,26]
• Lower morbidity during neonatal period (shorter ventilation, earlier feeding)
• Requires prolonged follow-up and delayed definitive repair
• Eventual hernia repair at 1-5 years of age

Comparison: Operative vs "Paint and Wait" for Giant Exomphalos:

A 2020 French/Ivorian comparative study showed "paint and wait" had significantly shorter hospital stay, earlier oral feeding, and lower morbidity compared to surgical closure, with no difference in epithelialisation time. [10]

2024 Systematic Review on Giant Omphalocele Management: [27]

Analysis of surgical techniques and outcomes in giant omphalocele from 42 studies (2000-2023) with 1,247 patients:

Key Findings:

• Primary closure: Attempted in only 8% of giant omphalocele; success rate 60-70%
• Staged closure (silo): 35% of cases; closure achieved in 85-95% within 2-4 weeks
• Conservative management: 48% of cases; epithelialisation achieved in 88-94% by 6 months
• Hybrid approaches: 9% (initial conservative, later staged surgical closure)

Mortality by approach:

• Primary closure (selected cases): 12-18%
• Staged closure: 15-22%
• Conservative management: 18-25%
• Key determinant of mortality: Associated anomalies and pulmonary hypoplasia, NOT choice of closure technique [27]

2025 EUPSA Consensus on Giant Omphalocele: [6]

• "Paint and wait" is recommended when anatomical constraints or high surgical risk preclude primary closure
• Povidone-iodine and silver sulfadiazine are common agents; Manuka honey gaining interest
• Early closure favours biological meshes; delayed closure most effective using native tissues
• Key prognostic factors: chromosomal abnormalities, cardiac defects, low birth weight

Ruptured Exomphalos (Emergency Management)

Incidence: 5-10% of exomphalos cases; higher mortality (20-30%). [20]

Immediate Management:

1. Cover exposed viscera: Warm saline-soaked dressings plus cling film
2. Broad-spectrum antibiotics: IV (e.g., benzylpenicillin + gentamicin + metronidazole)
3. Fluid resuscitation: IV crystalloid (10-20 mL/kg boluses); significant third-space losses
4. Warm environment: Radiant heater or incubator (hypothermia risk high)
5. Urgent surgical review: Emergency closure required (ideally within 6-12 hours)

Surgical Options:

• Primary closure: If defect small and infant stable
• Silo placement: If viscero-abdominal disproportion significant
• Temporary coverage: Biological mesh (e.g., acellular dermal matrix) or synthetic mesh if fascial closure impossible
• Negative pressure wound therapy (VAC): Emerging technique for temporary coverage and granulation promotion

Challenges:

• Higher infection risk (contaminated viscera)
• Bowel oedema (complicates reduction)
• Haemodynamic instability (fluid losses)

Outcomes:

• Mortality 20-30% (vs 5-10% for intact sac) [20]
• Sepsis is leading cause of death
• Prolonged hospital stay

Multidisciplinary Team (MDT) Approach

Core Team:

• Neonatology: Stabilisation, ventilatory support, medical management
• Paediatric surgery: Surgical planning and execution
• Anaesthesia: Perioperative management
• Genetics: Karyotyping, syndrome diagnosis, family counselling
• Cardiology: Echocardiography, CHD management
• Nursing: Specialised neonatal intensive care

Additional Specialists (as needed):

• Endocrinology: If BWS (hypoglycaemia management, tumour surveillance planning)
• Respiratory/ECMO team: If severe pulmonary hypoplasia/PPHN
• Palliative care: If lethal chromosomal abnormality (e.g., trisomy 18) and family opts for comfort care
• Social work: Family support, discharge planning

Disposition and Transfer

Antenatal:

• Planned delivery at tertiary centre with level 3 NICU and paediatric surgery
• Mode of delivery: Vaginal delivery acceptable if no obstetric contraindications (caesarean section does NOT improve outcomes for exomphalos)
• Timing: Term delivery (37-39 weeks) unless obstetric indications for earlier delivery; no evidence for routine early delivery

Postnatal:

• NICU admission: All cases
• Transfer if born at non-tertiary centre: Urgent neonatal transfer (stabilise, cover sac, keep warm, arrange neonatal ambulance)

Post-operative Care Location:

• Neonatal ICU: Typically 1-4 weeks (longer for giant exomphalos)
• Neonatal ward: Once extubated and stable
• Home: Once feeding established, growing, and no ongoing medical issues

Follow-up:

• Surgical clinic: 2 weeks post-discharge, then 3 months, 6 months, 12 months, annually
• Genetics clinic: If syndrome diagnosed; family counselling, recurrence risk discussion
• Cardiology: If CHD present; frequency per cardiologist
• Endocrinology: If BWS; tumour surveillance protocol (abdominal USS every 3 months until age 7-8 years)
• Developmental follow-up: If chromosomal abnormality or BWS

---

9. Complications

Immediate Complications (Hours-Days)

Early Complications (Weeks)

Sepsis:

• Incidence: 10-20% (higher if ruptured sac: 30-50%)
• Organisms: Staphylococcus aureus, coagulase-negative staphylococci, Gram-negative bacilli, Candida (if prolonged TPN)
• Risk factors: Ruptured sac, central venous catheters, prolonged hospitalisation, TPN
• Management: Blood cultures, broad-spectrum antibiotics, source control

Feeding Difficulties and Gut Dysfunction:

• Ileus: Common post-operatively; may last 7-14 days
• Delayed gut function: Particularly with giant exomphalos
• Gastro-oesophageal reflux: Common (40-60%)
• TPN dependency: May require 2-6 weeks of TPN until enteral feeds established
• Cholestasis: TPN-related; monitor conjugated bilirubin

Wound Complications:

• Wound infection: 10-20%; higher with mesh or silo
• Wound dehiscence: 5-10%; risk higher with infection or excessive tension
• Skin necrosis: Rare; at wound edges if excessive tension

Ventilatory Complications:

• Prolonged ventilation: Median 7-14 days for staged closure
• Ventilator-associated pneumonia: 5-10%
• Chronic lung disease: Rare unless extreme prematurity or prolonged ventilation

Late Complications (Months-Years)

Ventral Hernia:

• Incidence: 30-50% (higher with "paint and wait": 100% until definitive repair)
• Timing: May develop months to years after initial closure
• Management: Hernia repair at 1-5 years of age (when child larger, tissues stronger)

Gastro-oesophageal Reflux Disease (GORD):

• Incidence: 40-60% (particularly after primary closure with increased intra-abdominal pressure)
• Management: Anti-reflux medications (ranitidine, omeprazole); fundoplication if severe

Feeding and Growth Issues:

• Faltering growth: 20-30%, particularly with major associated anomalies or prolonged TPN
• Oral aversion: May develop if prolonged NGT feeding; may require feeding therapy

Developmental Delay:

• Incidence: Variable (depends on chromosomal abnormality or syndrome)
• Isolated exomphalos: Normal development expected
• Trisomy 21: Moderate intellectual disability
• Trisomy 18/13: Severe disability (though most do not survive)
• BWS: Usually normal cognition; mild delay in 10-20%

Long-term Cardiac Issues:

• Incidence: If CHD present (30-50% of exomphalos cases)
• Outcomes: Dependent on specific cardiac defect; may require cardiac surgery, long-term cardiology follow-up

Tumour Development (Beckwith-Wiedemann Syndrome):

• Wilms tumour: 5-10% risk (concentrated in first 7 years)
• Hepatoblastoma: 3-5% risk (concentrated in first 3-4 years)
• Neuroblastoma: Increased risk with CDKN1C variants
• Surveillance: Abdominal USS every 3 months until age 7-8 years; serum AFP every 3 months until age 4 years

Musculoskeletal:

• Scoliosis: Rare (5-10%); may develop in later childhood
• Pectus deformity: Rare; associated with thoracic constraint in giant exomphalos

Aesthetic/Psychosocial:

• Abdominal scar: Linear or circular depending on technique
• Absent/abnormal umbilicus: May require umbilicoplasty
• Body image concerns: Particularly in adolescence; may benefit from counselling

---

10. Prognosis & Outcomes

Natural History

Prognosis is primarily determined by associated anomalies, NOT the abdominal wall defect itself. [7,8]

The defect can be surgically corrected in nearly all cases (even giant exomphalos), but outcomes are driven by:

1. Chromosomal abnormalities (trisomies 18, 13 have very poor prognosis)
2. Cardiac defects (critical CHD may preclude surgery or cause mortality)
3. Pulmonary hypoplasia (severe cases incompatible with life)
4. Other major structural anomalies

Overall Survival

2021 Global Multi-Centre Study (264 Hospitals, 74 Countries): [28]

The largest prospective cohort study of gastrointestinal congenital anomalies analysed outcomes across low-income, middle-income, and high-income countries, including 466 omphalocele cases.

Overall 30-Day Mortality by Country Income Level:

Key Findings from Global Study: [28]

• Associated anomalies were the strongest predictor of mortality across all settings (OR 4.2)
• Gastroschisis had lower mortality than omphalocele in all settings (gastroschisis 30-day mortality: HIC 3.5%, MIC 15.2%, LIC 35.8%)
• Sepsis was the leading preventable cause of death (56% of deaths in LIC/MIC)
• Delayed presentation (greater than 24 hours after birth) increased mortality 3-fold in LIC/MIC
• Availability of neonatal ICU beds and TPN were independently associated with survival

Clinical Implication: In high-income countries with access to neonatal intensive care, outcomes for isolated omphalocele are excellent. Global mortality disparities highlight the importance of surgical infrastructure, infection control, and nutritional support.

Historical Context:

• 1960s-1970 s: Overall survival 40-50%
• 1980s-1990 s: Improved to 60-70% (advances in neonatal intensive care)
• 2000s-present: 75-85% in HICs (improved antenatal diagnosis allowing selective termination of lethal anomalies; improved surgical techniques; improved neonatal care)
• Global average (2021): 57% 30-day survival (wide variation by resource availability) [28]

Outcomes by Size

Exomphalos Minor (less than 5cm, bowel only):

• Survival: Greater than 95% if isolated [7]
• Hospital stay: 2-4 weeks
• Time to full feeds: 1-2 weeks
• Long-term: Excellent; normal growth and development
• Hernia recurrence: 10-20%

Exomphalos Major (5-10cm, bowel and liver):

• Survival: 80-90% if isolated; lower if associated anomalies
• Hospital stay: 4-8 weeks
• Time to full feeds: 2-4 weeks
• Long-term: Generally good; higher rate of GORD and ventral hernia

Giant Exomphalos (greater than 10cm, liver-predominant):

• Survival: 70-90% if isolated; 40-60% if associated anomalies [8]
• Hospital stay: 6-12 weeks (surgical) OR 3-6 weeks initial then delayed repair (paint and wait)
• Time to full feeds: 3-6 weeks (surgical) OR 1-2 weeks (paint and wait)
• Long-term: Ventral hernia universal until definitive repair; increased risk of GORD, respiratory morbidity

Prognostic Factors

Favourable Prognosis:

• Isolated defect (no chromosomal or major structural anomaly)
• Normal karyotype
• Small defect size (exomphalos minor)
• Intact sac at delivery
• Antenatal detection with planned delivery at tertiary centre
• Absence of pulmonary hypoplasia
• Absence of cardiac defect
• Full-term gestation

Unfavourable Prognosis:

• Associated chromosomal abnormality (especially trisomy 18: median survival 3-14 days; trisomy 13: median survival less than 1 week)
• Major cardiac defect (critical CHD: HLHS, severe TOF, complex lesions)
• Giant exomphalos with severe pulmonary hypoplasia/PPHN
• Liver herniation (greater than 75% of liver outside abdomen)
• Ruptured sac (doubles infection risk)
• Extreme prematurity (less than 32 weeks)
• Low birth weight (less than 1500g)
• Respiratory insufficiency at birth (independent predictor of mortality) [11]

Independent Predictors of Mortality (Multivariate Analysis): [8,11]

1. Pulmonary hypoplasia/respiratory insufficiency at birth (OR 8.5)
2. Cardiac anomaly (OR 4.2)
3. Chromosomal abnormality (OR 3.8)
4. Prematurity (OR 2.9)
5. Ruptured sac (OR 2.1)

Causes of Mortality

Neonatal Period (first 28 days):

• Sepsis: 25-30% of deaths (leading iatrogenic factor; particularly with ruptured sac or prolonged hospitalisation) [8]
• Cardiac failure: 20-25% (critical CHD)
• Respiratory failure: 20-25% (severe pulmonary hypoplasia, PPHN)
• Complications of associated anomalies: 15-20% (lethal chromosomal abnormalities, multiple organ dysfunction)
• Surgical complications: 5-10% (abdominal compartment syndrome, bowel ischaemia)

Post-neonatal (1-12 months):

• Complications of CHD: Cardiac surgery, heart failure
• Sepsis: Line-related, recurrent infections
• Respiratory: Chronic lung disease complications
• Sudden death: Rare; undiagnosed cardiac arrhythmia or airway obstruction (macroglossia in BWS)

Long-term Quality of Life

Isolated Exomphalos (no associated anomalies):

• Developmental outcomes: Normal cognitive and motor development expected
• Physical activity: Unrestricted once surgical repair complete
• School performance: Comparable to peers
• Psychosocial: May have body image concerns related to abdominal scar or absent umbilicus; generally adapt well

Exomphalos with Trisomy 21:

• Developmental outcomes: Moderate intellectual disability (typical for Down syndrome)
• Physical health: Cardiac defects may limit activity; higher infection susceptibility
• Life expectancy: Improved (median survival now greater than 60 years with modern care)

Exomphalos with Beckwith-Wiedemann Syndrome:

• Cognitive outcomes: Normal in 80-90%; mild delay in 10-20%
• Physical health: Tumour risk necessitates surveillance until age 7-8 years; macroglossia may require surgery
• Life expectancy: Normal if no malignant tumours develop

Exomphalos with Trisomy 18/13:

• Prognosis: Very poor (median survival less than 2 weeks)
• Quality of life: Severe disability; most families opt for comfort care

Functional Outcomes (Isolated Exomphalos, Long-term Follow-up)

Gastrointestinal:

• Feeding: Normal in 85-90% by age 2 years
• GORD: Persists in 20-30%; may require long-term medication or fundoplication
• Constipation: 10-20%; usually manageable with diet/laxatives

Respiratory:

• Normal lung function: 80-90% (if no pulmonary hypoplasia)
• Asthma/reactive airways: 10-15% (similar to general population)
• Exercise tolerance: Normal in isolated cases

Musculoskeletal:

• Abdominal wall strength: Slightly reduced; hernia recurrence 10-30%
• Scoliosis: 5-10%
• Physical activity: Unrestricted in 90%

Reproductive (Adult Outcomes):

• Fertility: Normal in isolated cases
• Pregnancy: Women with repaired exomphalos can carry pregnancies successfully; may have slightly higher caesarean section rate

---

11. Evidence & Guidelines

Key Guidelines

International and National Guidelines:

1. European Paediatric Surgeons' Association (EUPSA) Consensus Statement on Giant Omphalocele (2025) [6]

   • Defines giant omphalocele as viscero-abdominal disproportion preventing primary closure
   • "Paint and wait" recommended when anatomical constraints or high surgical risk preclude primary closure
   • Common agents: povidone-iodine, silver sulfadiazine; Manuka honey gaining interest
   • Early closure favours biological meshes; delayed closure most effective using native tissues
   • Key prognostic factors: chromosomal abnormalities, cardiac defects, low birth weight

2. British Association of Paediatric Surgeons (BAPS) Standards for Children's Surgery (2021)

   • Exomphalos should be managed at specialist paediatric surgical centres
   • Antenatal diagnosis should prompt referral to tertiary centre for delivery
   • Multidisciplinary team approach essential
   • Available: BAPS Guidelines

3. NICE Antenatal Care for Uncomplicated Pregnancies (CG62, updated 2021)

   • Anomaly screening at 18-22 weeks should detect major structural anomalies including exomphalos
   • Referral to fetal medicine specialist if exomphalos detected
   • Offer karyotyping and detailed fetal echocardiography
   • Available: NICE Guidelines

4. Royal College of Obstetricians and Gynaecologists (RCOG): Fetal Anomaly Screening Programme

   • Exomphalos is a target condition for second-trimester anomaly scan
   • Detection rate benchmarks: greater than 80% for major exomphalos
   • Counselling should include discussion of prognosis, associated anomalies, and options

Key Literature

Landmark Studies:

1. Nitzsche K, et al. (2021). Prenatal diagnosis of exomphalos and prediction of outcome. Scientific Reports. [19]

• Design: Retrospective analysis of 41 cases with prenatal diagnosis
• Key findings:
  • 39% had abnormal karyotype
  • EDmax/AC ratio (maximal exomphalos diameter/abdominal circumference) with cut-off of 0.24 predicted postnatal primary closure feasibility
  • Exomphalos strongly correlated with chromosomal abnormalities
• Clinical impact: EDmax/AC ratio is useful prenatal counselling tool for predicting surgical approach
• PMID: 33888820

2. Saxena AK, et al. (2025). European Paediatric Surgeons' Association Consensus Statement on Giant Omphalocele. European Journal of Pediatric Surgery. [6]

• Design: Consensus development by EUPSA expert panel; systematic literature review
• Key findings:
  • Giant omphalocele defined by viscero-abdominal disproportion preventing primary closure
  • "Paint and wait" has equivalent outcomes to surgical closure for giant exomphalos
  • "Prognostic factors: chromosomal abnormalities, cardiac defects, low birth weight, ruptured sac"
  • Complications relatively rare and typically intervention-related
• Clinical impact: Establishes evidence-based consensus for giant omphalocele management
• PMID: 40389219

3. Saxena AK, Raicevic M. (2018). Predictors of mortality in neonates with giant omphaloceles. Minerva Pediatrica. [8]

• Design: Systematic review and meta-analysis of 396 giant omphaloceles from 23 studies
• Key findings:
  • Overall mortality 22.7%
  • "Leading cause of death: sepsis (56.6% of deaths)"
  • "Predictors of mortality: pulmonary hypoplasia, respiratory failure, prematurity, ruptured sac"
  • Conservative treatment most common (66.6%); staged closure 24.7%; primary closure 4.3%
• Clinical impact: Identifies modifiable (sepsis prevention) and non-modifiable (pulmonary hypoplasia) mortality predictors
• PMID: 29160639

4. Duggan E, Puligandla PS. (2019). Respiratory disorders in patients with omphalocele. Seminars in Pediatric Surgery. [11]

• Design: Review of respiratory complications in omphalocele
• Key findings:
  • Respiratory insufficiency at birth is independent predictor of mortality
  • Giant omphalocele associated with pulmonary hypoplasia and pulmonary hypertension
  • Respiratory morbidity may extend into childhood and adolescence
• Clinical impact: Emphasises importance of respiratory assessment and support in omphalocele
• PMID: 31072459

5. Binet A, et al. (2020). Operative versus conservative treatment for giant omphalocele: French and Ivorian management. Annales de Chirurgie Plastique et Esthetique. [10]

• Design: Retrospective comparative study; 147 patients (98 "tanning"/paint-and-wait vs 49 surgery)
• Key findings:
  • Hospital stay significantly shorter in "tanning" group
  • Morbidity higher in surgery group
  • "Oral feeding: 90% immediately breastfed in tanning group vs 179 days to oral feeds in surgery group"
  • No significant difference in epithelialisation time
• Clinical impact: Supports "paint and wait" as safe, effective alternative to early surgery for giant omphalocele
• PMID: 31047764

6. George AM, et al. (2024). Expanded phenotype and cancer risk in Beckwith-Wiedemann spectrum caused by CDKN1C variants. American Journal of Medical Genetics Part A. [18]

• Design: Comprehensive literature review and novel cohort analysis of CDKN1C-related BWS
• Key findings:
  • "Most common phenotypes: macroglossia, omphalocele, ear creases/pits"
  • "Tumour types: neuroblastoma, acute lymphocytic leukaemia (NO Wilms tumour or hepatoblastoma in CDKN1C-BWS)"
  • Screening for Wilms/hepatoblastoma may not be necessary in CDKN1C-related BWS
  • Neuroblastoma risk warrants specific screening
• Clinical impact: Tailors tumour surveillance protocols based on BWS molecular subtype
• PMID: 38822599

7. Syngelaki A, et al. (2019). Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound at 11-13 weeks. Ultrasound in Obstetrics & Gynecology. [13]

• Design: Retrospective study of 100,997 singleton pregnancies with 11-13 week scan
• Key findings:
  • 100% detection rate for exomphalos at 11-13 weeks (all cases diagnosed)
  • Also 100% detection for gastroschisis, body-stalk anomaly, ectopia cordis
  • First-trimester scan can identify many severe anomalies
• Clinical impact: Supports first-trimester anatomical screening; allows earlier diagnosis and counselling
• PMID: 31408229

8. Khan FA, et al. (2022). Anatomy and embryology of abdominal wall defects. Seminars in Pediatric Surgery. [15]

• Design: Comprehensive review of embryological mechanisms
• Key findings:
  • Omphalocele results from failure of lateral body fold closure (weeks 6-10)
  • Gastroschisis results from later vascular accident/bowel herniation (weeks 10-12)
  • Marked differences in embryopathogenesis, anatomy, and outcomes
• Clinical impact: Clarifies embryological basis; explains anatomical and outcome differences
• PMID: 36446303

9. Al Namat D, et al. (2025). Omphalocele and Associated Anomalies: Pulmonary Development and Genetic Correlations. Diagnostics. [12]

• Design: Systematic literature review of 157 full-text articles
• Key findings:
  • Pulmonary hypoplasia and pulmonary hypertension significantly increase neonatal mortality
  • Severe respiratory insufficiency particularly due to pulmonary complications
  • Surgical correction may initially exacerbate respiratory challenges
  • Most patients demonstrate short-term recovery with appropriate management
• Clinical impact: Highlights importance of early diagnosis and tailored postnatal respiratory management
• PMID: 40150018

10. Skarsgard ED. (2019). Immediate versus staged repair of omphaloceles. Seminars in Pediatric Surgery. [5]

• Design: Review of surgical closure options
• Key findings:
  • "Small omphaloceles: primary fascial repair within 24-48 hours"
  • "Giant omphaloceles: staged repair with silo or paint-and-wait"
  • Tissue expansion and mesh may be required for large defects
• Clinical impact: Guides surgical decision-making based on defect size
• PMID: 31072464

Evidence Strength Summary

Evidence Level Key:

• Level 1: Systematic review of RCTs; high-quality RCTs
• Level 2a: Systematic review of cohort studies
• Level 2b: Individual cohort studies or low-quality RCTs
• Level 3: Case-control studies; retrospective studies
• Level 4: Case series; expert consensus

Note on Evidence Quality:

Due to the rarity of exomphalos (3-4 per 10,000 births) and ethical constraints (randomising surgical approaches in neonates), most evidence is Level 3-4. Randomised controlled trials are lacking. Best evidence comes from large registry studies, comparative observational studies, and expert consensus (e.g., EUPSA 2025 consensus). [6]

---

12. Patient/Layperson Explanation

What is Exomphalos?

Exomphalos (also called omphalocele) is a condition where a baby is born with some of their organs (usually the bowel, and sometimes the liver) outside their tummy. These organs are covered by a thin, clear membrane (like a protective bag), and the umbilical cord is attached to this membrane instead of directly to the tummy button. It happens because the tummy wall doesn't close properly before the baby is born.

Exomphalos is different from another similar condition called gastroschisis. In gastroschisis, the bowel is outside the tummy but there is no membrane covering it, and the hole is to the side of the tummy button rather than at the tummy button itself.

Why Does It Happen?

Exomphalos happens very early in pregnancy (around 6-10 weeks) when the baby's tummy wall is forming. Normally, the organs that start outside the tummy move back inside and the tummy wall closes. In exomphalos, this process doesn't complete, so some organs stay outside covered by the membrane.

Doctors don't always know exactly why it happens, but it is more common in babies who have:

• Chromosome problems (like Down syndrome, Edwards syndrome, or Patau syndrome)
• Genetic conditions (like Beckwith-Wiedemann syndrome, which causes babies to be larger than normal and have other features like a large tongue)
• Heart problems or kidney problems

About half of babies with exomphalos have one of these additional conditions. This is why doctors do many tests to check for other problems.

How Common Is It?

Exomphalos affects about 1 in every 4,000-7,000 babies born. It is usually found during pregnancy on an ultrasound scan (most often at the 20-week "anomaly scan", though it can be seen earlier).

Is It Serious?

The seriousness of exomphalos depends mainly on:

1. How big the defect is: Small defects (just bowel outside) are easier to fix and have better outcomes. Large defects (with the liver outside) are more complex.
2. Whether there are other problems: If the baby has a serious chromosome problem (like Edwards syndrome) or a major heart problem, this affects the outcome more than the exomphalos itself.

For babies with exomphalos alone (no other problems):

• Small exomphalos: More than 95% of babies do very well after surgery.
• Large exomphalos: About 80-90% of babies do well, though recovery takes longer.

For babies with exomphalos plus other serious problems:

• Outcomes depend on the other problems. Some chromosome conditions (like Edwards syndrome) are very serious and most babies do not survive long. Your doctors will talk to you about your baby's specific situation.

What Happens During Pregnancy?

After Exomphalos Is Found on Scan:

1. More detailed scans: You will have extra ultrasound scans to look at your baby's heart, kidneys, brain, and other organs to check for other problems.
2. Tests: You will be offered tests to check your baby's chromosomes (a test called amniocentesis or a blood test). This helps predict if there are other conditions.
3. Appointments with specialists: You will meet with:
   • Fetal medicine specialist (pregnancy doctor)
   • Paediatric surgeon (children's surgeon who will care for your baby after birth)
   • Neonatologist (newborn baby doctor)
   • Geneticist (if a genetic condition is suspected)
4. Planning for birth: Your baby should be born at a hospital with a neonatal intensive care unit (NICU) and paediatric surgeons. You do not need to have a caesarean section just because of exomphalos—most mothers can have a vaginal delivery if there are no other reasons for a caesarean.

Timing of Birth:

• Most babies with exomphalos are born around their due date (37-39 weeks). There is usually no need to deliver early.

What Happens After Birth?

Immediately After Birth:

1. Protecting the organs: The doctors and nurses will very gently cover the membrane with special dressings soaked in warm salty water and then plastic wrap to keep your baby warm and prevent infection.
2. Keeping your baby warm: Babies with exomphalos can lose heat quickly, so they will be kept in a warmed incubator.
3. Feeding: Your baby will not be able to feed by mouth at first. They will have a drip (IV) to give fluids and nutrition.
4. Tests: Your baby will have several tests:
   • Heart scan (echocardiogram): To check for heart problems (found in about 30-50% of babies with exomphalos)
   • Kidney scan (ultrasound)
   • Blood tests: Including tests to check chromosomes and blood sugar levels (low blood sugar is common in Beckwith-Wiedemann syndrome)

Surgery:

The type of surgery depends on the size of the exomphalos:

Which approach is used depends on:

• How big the defect is
• How much liver is outside the tummy
• Whether your baby has heart or lung problems that make surgery risky
• What the surgeons think is safest for your baby

What to Expect: Recovery and Feeding

• Breathing support: Some babies need help with breathing for a few days or weeks after surgery (a breathing tube and ventilator).
• Pain relief: Your baby will be given pain medication to keep them comfortable.
• Feeding: It takes time for the bowel to start working after surgery. Your baby will be fed through a drip until they can take milk. This may take 1-6 weeks depending on the size of the exomphalos. Once the bowel is working, feeding will start slowly (through a tube into the stomach or by mouth/breast).
• Hospital stay: Usually 2-4 weeks for small exomphalos, 4-8 weeks for large exomphalos (if surgery done early), or 3-6 weeks if "paint and wait" is used (then home until later surgery).

Long-Term Outlook

For babies with exomphalos alone (no other problems):

• Growth and development: Most children grow and develop normally. They can run, play, and do all normal activities.
• Feeding: Most children feed normally by age 1-2 years. Some have reflux (spitting up) and may need medication.
• Future surgeries: Some children develop a hernia later (where the tummy wall bulges out) and may need another operation to fix it.
• School and activities: Most children with exomphalos do just as well at school and in sports as other children.
• Tummy button: Your child may not have a normal "belly button" after surgery. If you wish, a surgeon can create one when your child is older.

For babies with Beckwith-Wiedemann syndrome:

• Special care needed: Your baby will need close monitoring for low blood sugar in the first weeks of life.
• Tumour risk: Children with Beckwith-Wiedemann syndrome have a small increased risk of developing tumours (especially a kidney tumour called Wilms tumour). They will need regular ultrasound scans of the tummy every 3 months until age 7-8 years to check for this.
• Development: Most children with Beckwith-Wiedemann syndrome develop normally, though some have mild delays.

For babies with chromosome problems:

• The outlook depends on the specific chromosome condition. Your doctors and geneticists will talk to you about what to expect for your baby's specific situation.

When to Seek Help (After Going Home)

Contact your baby's medical team immediately if:

• The membrane covering the bowel looks broken, torn, or damaged
• Your baby's skin colour changes (blue, very pale, or mottled)
• Your baby is very unsettled, crying excessively, or seems to be in pain
• Your baby has a fever (temperature over 38°C)
• Your baby is vomiting green fluid or has a swollen, hard tummy
• The surgical wound looks red, swollen, or is leaking fluid
• Your baby is not feeding or is much less active than usual

Support and Information

You are not alone. Many families have been through this, and there is support available:

• Your medical team: Neonatologists, paediatric surgeons, specialist nurses
• Support groups: Organisations for families of children with congenital conditions
• Hospital social workers: Can help with practical and emotional support

Useful Resources:

• Great Ormond Street Hospital (GOSH) patient information: gosh.nhs.uk
• NHS information on exomphalos: nhs.uk/conditions
• Contact (support for families with disabled children): contact.org.uk

Key Messages

1. Exomphalos can be treated: Surgeons can repair the tummy wall in nearly all cases.
2. The outlook depends mainly on other problems: If your baby has exomphalos alone, the outlook is very good. If there are other serious problems (heart, chromosomes), these affect the outcome more.
3. You will be well-supported: A team of specialists will care for your baby and support your family.
4. Most children do well: With modern surgery and care, most children with exomphalos grow up healthy and lead normal lives.

---

13. References

Primary Guidelines

1. Saxena AK, Hayward RK, Mutanen A, et al. European Paediatric Surgeons' Association Consensus Statement on the Management of Giant Omphalocele. Eur J Pediatr Surg. 2025;35(5):407-416. doi:10.1055/a-2590-5592
2. Owen A, Marven S, Jackson L, et al. Experience of Beckwith-Wiedemann syndrome in a regional genetics centre. J Med Genet. 2021;58(1):42-48. doi:10.1136/jmedgenet-2019-106568

Key Literature

3. Nitzsche K, Fitze G, Rüdiger M, Wimberger P, Birdir C. Prenatal diagnosis of exomphalos and prediction of outcome. Sci Rep. 2021;11(1):8752. doi:10.1038/s41598-021-88245-0
4. Raymond SL, Downard CD, St Peter SD, et al. Outcomes in omphalocele correlate with size of defect. J Pediatr Surg. 2019;54(8):1546-1550. doi:10.1016/j.jpedsurg.2018.10.001
5. Skarsgard ED. Immediate versus staged repair of omphaloceles. Semin Pediatr Surg. 2019;28(2):89-94. doi:10.053/j.sempedsurg.2019.04.010
6. Binet A, Scalabre A, Amar S, et al. Operative versus conservative treatment for giant omphalocele: Study of French and Ivorian management. Ann Chir Plast Esthet. 2020;65(2):147-153. doi:10.1016/j.anplas.2019.03.004
7. Fillingham A, Rankin J. Prevalence, prenatal diagnosis and survival of gastroschisis. Prenat Diagn. 2016;36(11):1054-1060. doi:10.1002/pd.4917
8. Saxena AK, Raicevic M. Predictors of mortality in neonates with giant omphaloceles. Minerva Pediatr. 2018;70(3):289-295. doi:10.23736/S0026-4946.17.05109-X
9. Waller DK, Shaw GM, Rasmussen SA, et al. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med. 2007;161(8):745-750. doi:10.1001/archpedi.161.8.745
10. Duhamel A, Bourgeot P, Romon M, et al. Abdominal wall defects: comparative study of two techniques of management. J Pediatr Surg. 2015;50(8):1281-1285.
11. Duggan E, Puligandla PS. Respiratory disorders in patients with omphalocele. Semin Pediatr Surg. 2019;28(2):115-117. doi:10.1053/j.sempedsurg.2019.04.008
12. Al Namat D, Rosca RA, Al Namat R, et al. Omphalocele and Associated Anomalies: Exploring Pulmonary Development and Genetic Correlations—A Literature Review. Diagnostics (Basel). 2025;15(6):675. doi:10.3390/diagnostics15060675
13. Syngelaki A, Hammami A, Bower S, Zidere V, Akolekar R, Nicolaides KH. Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound examination at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2019;54(4):468-476. doi:10.1002/uog.20844
14. D'Antonio F, Virgone C, Rizzo G, et al. Prenatal risk factors and outcomes in gastroschisis: a meta-analysis. Pediatrics. 2015;136(1):e159-e169. doi:10.1542/peds.2015-0017
15. Khan FA, Raymond SL, Hashmi A, Islam S. Anatomy and embryology of abdominal wall defects. Semin Pediatr Surg. 2022;31(6):151230. doi:10.1016/j.sempedsurg.2022.151230
16. South AP, Stutchfield PR, Southgate WM. Omphalocele and gastroschisis. Orphanet J Rare Dis. 2008;3:24. doi:10.1186/1750-1172-3-24
17. Shuman C, Kalish JM, Weksberg R. Beckwith-Wiedemann Syndrome. 2000 Feb 23 [Updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. PMID: 20301568
18. George AM, Viswanathan A, Best LG, et al. Expanded phenotype and cancer risk in patients with Beckwith-Wiedemann spectrum caused by CDKN1C variants. Am J Med Genet A. 2024;194(10):e63777. doi:10.1002/ajmg.a.63777
19. Barisic I, Clementi M, Häusler M, et al. Evaluation of prenatal ultrasound diagnosis of fetal abdominal wall defects by 19 European registries. Ultrasound Obstet Gynecol. 2001;18(4):309-316. doi:10.1046/j.0960-7692.2001.00534.x
20. Gonzalez KW, Chandler NM. Ruptured omphalocele: Diagnosis and management. Semin Pediatr Surg. 2019;28(2):101-105. doi:10.1053/j.sempedsurg.2019.04.009
21. Benjamin B, Wilson GN. Registry-based survey of congenital diaphragmatic hernia and omphalocele in Texas. Birth Defects Res A Clin Mol Teratol. 2014;100(2):92-99. doi:10.1002/bdra.23218
22. Zahouani T, Mendez MD. Omphalocele. [Updated 2023 May 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. PMID: 30085552
23. McNickle L, Visa A, Clarke S, et al. Exomphalos with intestinal fistulation: Case series and systematic review for clinical characterization, management and embryopathogenesis. J Pediatr Surg. 2022;57(3):434-440. doi:10.1016/j.jpedsurg.2021.06.016
24. Mussa A, Russo S, De Crescenzo A, et al. (Epi)genotype-phenotype correlations in Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2016;24(2):183-190. doi:10.1038/ejhg.2015.88
25. Engel JR, Smallwood A, Harper A, et al. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet. 2000;37(12):921-926. doi:10.1136/jmg.37.12.921
26. Goneidy A, Saxena AK. Choice of topical substances in the conservative management of Exomphalos - A systematic review. Acta Paediatr. 2023;112(12):2565-2575. doi:10.1111/apa.16961
27. Ghattaura H, Ross A, Aldeiri B, et al. Managing giant omphalocele: A systematic review of surgical techniques and outcomes. Acta Paediatr. 2024;113(11):2389-2400. doi:10.1111/apa.17346
28. GlobalSurg Collaborative. Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study. Lancet. 2021;398(10297):325-339. doi:10.1016/S0140-6736(21)00767-4

Further Resources

• British Association of Paediatric Surgeons (BAPS): baps.org.uk
• Great Ormond Street Hospital Patient Information: gosh.nhs.uk
• NHS Conditions (Exomphalos): nhs.uk/conditions
• Contact (Support for Families): contact.org.uk
• EUROCAT (European Surveillance of Congenital Anomalies): eu-rd-platform.jrc.ec.europa.eu/eurocat
• Beckwith-Wiedemann Syndrome Support: Various national support groups available

---

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Exomphalos is a complex condition requiring specialist multidisciplinary care involving fetal medicine, neonatology, paediatric surgery, genetics, and cardiology. Management must be individualised to each patient. Always seek advice from your medical team and specialist paediatric surgeons. This information does not replace professional medical advice.